Inhibitors of LonP1 and NCLX may be used as potential adjuvants to cisplatin therapy to avoid chemoresistance and enhance the curative effect in patients with oral cancer [87]. This evidence concerns the gene SLC8B1 and lip and oral cavity carcinoma.